登录 | 注册    关注公众号  
微信公众号
搜索
 > 【ADAM17】

ADAM17信息

英文名称:Disintegrin and metalloproteinase domain-containing protein 17
中文名称:去整合素和金属蛋白酶-17
靶点别称:EC:3.4.24.86,ADAM17 Protein,ADAM 17,Snake venom-like protease,CSVP,CD156b,ADAM17,ADAM Metallopeptidase Domain 17,TNF-Alpha Convertase,TACE,TNF-Alpha Converting Enzyme,TNF-Alpha-Converting Enzyme,CD156b Antigen,EC 3.4.24.86,NISBD1,NISBD,Disintegrin and metalloproteinase domain-containing protein 17,Tumor Necrosis Factor, Alpha, Converting Enzyme,ADAM Metallopeptidase Domain 18,ADAM18
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

ADAM17产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
AD7-M52H1
Mouse
Mouse ADAM17 / TACE / CD156b Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

ADAM17 分子别名

ADAM17,TACE,CD156b

ADAM17 分子背景

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

ADAM17 前沿进展

ADAM17临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Aderbasib INCB-7839; INC-B007839; INCB-007839 临床二期 Incyte Corp 实体瘤, 肿瘤, 胶质母细胞瘤, 弥漫性大B-细胞淋巴瘤, 少突神经胶质瘤, 乳腺癌, 星形细胞瘤, 弥漫性内源性庞汀胶质瘤, 胶质瘤 详情
ORYN-1001 ORTD-1; ORYN-1001 临床一期 Oryn Therapeutics Llc 新型冠状病毒感染, 类风湿关节炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定